2011 SGO News: PARP Inhibitor Active in Ovarian Cancer
2011 SGO News: PARP Inhibitor Active in Ovarian Cancer
Almost half of patients with heavily pretreated ovarian cancer benefited from an investigational PARP inhibitor, results of a phase I study showed.